Concord Healthcare Group Co Ltd

Concord Healthcare Group Co Ltd has a market price of 1.36 and a market cap of 1.07 billion, with a price-to-book ratio of 0.58 and a price-to-tangible-book ratio of 0.58. The company's enterprise value to EBITDA is negative at -22.75, and its enterprise value to revenue is 9.03. The company's return on equity is -14.02%, and its return on assets is -4.43%. The debt-to-equity ratio is 1.69, and the current ratio is 0.54, indicating potential liquidity challenges. The company's operating income is -182.68 million, and its net income is -256.60 million, reflecting a significant decline in profitability. The return on equity and return on assets are below the industry median, indicating underperformance in capital efficiency and asset utilization. The company's operating cash flow is -113.08 million, and its free cash flow is -299.57 million, suggesting a lack of cash generation. Concord Healthcare Group Co Ltd operates primarily in the domestic market, with its Hospital Business segment serving cancer patients through self-operated medical institutions and its Medical Equipment, Software and Related Services segment engaged in the sales and installation of medical equipment and software. The company's revenue is concentrated in these two segments, with no significant geographic diversification. The company's revenue is 459.92 million, and its capital expenditure is -146.87 million, indicating a focus on maintaining rather than expanding its operations. The company's outlook for the current fiscal year is negative, with a projected decline in revenue and profitability. The company's liquidity risk is medium, and its dilution risk is low, with no near-term pressure for additional equity issuance. The company's recent filings and transcripts indicate a focus on cost management and operational efficiency to improve its financial performance. The company has not disclosed any significant new projects or strategic initiatives in its recent filings.